Association between -174 interleukin-6 gene polymorphism and biological response to rituximab in several systemic autoimmune diseases

DNA and Cell Biology

Volumn 31, Issue 9, 2012, Pages 1486-1491

  Robledo, Gema ^a   Dávila Fajardo, Cristina Lucía ^a,b   Márquez, Ana ^a   Ortego Centeno, Norberto ^b   Callejas Rubio, José Luis ^b   De Ramón Garrido, Enrique ^c   Sánchez Román, Julio ^d   García Hernández, Francisco J ^d   Ríos Fernández, Raquel ^b   González Escribano, Maria Francisca ^d   Camps García, Maria Teresa ^c   Castillo Palma, Maria Jesús ^d   Ayala, Maria Del Mar ^c   Martín, Javier ^a  

^a INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

^b HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^c HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DNA; IMMUNOGLOBULIN; INTERLEUKIN 6; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID; RITUXIMAB; THALIDOMIDE;

ANCA ASSOCIATED VASCULITIS; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE HEMOLYTIC ANEMIA; BIOLOGICAL THERAPY; CORRELATION ANALYSIS; DNA POLYMORPHISM; DRUG EFFICACY; FEMALE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MYOSITIS; PLASMAPHERESIS; PRIORITY JOURNAL; PROMOTER REGION; RHEUMATOID ARTHRITIS; SINGLE NUCLEOTIDE POLYMORPHISM; SJOEGREN SYNDROME; SPAIN; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; AUTOIMMUNE DISEASES; FEMALE; GENE FREQUENCY; HUMANS; INTERLEUKIN-6; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; TREATMENT OUTCOME;

EID: 84865798726     PISSN: 10445498     EISSN: 15577430     Source Type: Journal    
DOI: 10.1089/dna.2012.1684     Document Type: Article

References (32)

1. Barnes, T. C., Anderson, M. E., and Moots, R. J. (2011). The many faces of interleukin-6: the role of IL-6 in inflammation, vasculopathy, and fibrosis in systemic sclerosis. Int J Rheumatol 2011, 6. 721608.
2. Dayer, E., Dayer, J. M., and Roux-Lombard, P. (2007). Primer: the practical use of biological markers of rheumatic and systemic inflammatory diseases. Nat Clin Pract Rheumatol 3, 512-520. (Pubitemid 47351396)
3. De Vita, S., Zaja, F., Sacco, S., De Candia, A., Fanin, R., and Ferraccioli, G. (2002). Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells. Arthritis Rheum 46, 2029-2033.
4. Diaz-Lagares, C., Croca, S., Sangle, S., Vital, E. M., Catapano, F., Martinez-Berriotxoa, A., Garcia-Hernandez, F., Callejas-Rubio, J. L., Rascon, J., D'Cruz, D., Jayne, D., Ruiz-Irastorza, G., Emery, P., Isenberg, D., Ramos-Casals, M., and Khamashta, M. A. (2012) Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts. Autoimmun Rev 11, 357-364.
5. Ezeonyeji, A. N., and Isenberg, D. A. (2012). Early treatment with rituximab in newly diagnosed systemic lupus erythematosus patients: a steroid-sparing regimen. Rheumatology (Oxford) 51, 476-481.
6. Fabris, M., Quartuccio, L., Lombardi, S., Benucci, M., Manfredi, M., Saracco, M., Atzeni, F., Morassi, P., Cimmino, M. A., Pontarini, E., Fabro, C., Pellerito, R., Sarzi-Puttini, P., Cutolo, M., Carletto, A., Bambara, L. M., Fischetti, F., Curcio, F., Tonutti, E., and De Vita, S. (2010) Study on the possible role of the -174G >C IL-6 promoter polymorphism in predicting response to rituximab in rheumatoid arthritis. Reumatismo 62, 253-258.
7. Fabris, M., Quartuccio, L., Lombardi, S., Saracco, M., Atzeni, F., Carletto, A., Cimmino, M., Fabro, C., Pontarini, E., Pellerito, R., Bambara, L. M., Sarzi-Puttini, P., Cutolo, M., Manfredi, M., Benucci, M., Morassi, P., Fischetti, F., Padovan, M., Govoni, M., Curcio, F., Tonutti, E., and De Vita, S. (2012) The CC homozygosis of the - 174G >C IL-6 polymorphism predicts a lower efficacy of rituximab therapy in rheumatoid arthritis. Autoimmun Rev 11, 315-320.
8. Fabris, M., Quartuccio, L., Saracco, M., Pellerito, R., Atzeni, F., Sarzi-Puttini, P., Cimmino, M. (2009). BLyS promoter polymorphism and response to rituximab in rheumatoid arthritis (RA) patients positive or negative for the rheumatoid factor. Arthritis Rheum Suppl 10, 1678.
9. Fishman, D., Faulds, G., Jeffery, R., Mohamed-Ali, V., Yudkin, J. S., Humphries, S., and Woo, P. (1998). The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 102, 1369-1376. (Pubitemid 28467565)
10. Fonseca, J. E., Santos, M. J., Canhao, H., and Choy, E. (2009). Interleukin-6 as a key player in systemic inflammation and joint destruction. Autoimmun Rev 8, 538-542.
11. Genovese, M. C., McKay, J. D., Nasonov, E. L., Mysler, E. F., da Silva, N. A., Alecock, E., Woodworth, T., and Gomez-Reino, J. J. (2008) Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 58, 2968-2980.
12. Gurcan, H. M., Keskin, D. B., Stern, J. N., Nitzberg, M. A., Shekhani, H., and Ahmed, A. R. (2009). A review of the current use of rituximab in autoimmune diseases. Int Immunopharmacol 9, 10-25.
13. Hellmich, B., Flossmann, O., Gross, W. L., Bacon, P., Cohen-Tervaert, J. W., Guillevin, L., Jayne, D., Mahr, A., Merkel, P. A., Raspe, H., Scott, D. G., Witter, J., Yazici, H., and Luqmani, R. A. (2007) EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis 66, 605-617. (Pubitemid 46707128)
14. Jones, G., Sebba, A., Gu, J., Lowenstein, M. B., Calvo, A., Gomez-Reino, J. J., Siri, D. A., Tomsic, M., Alecock, E., Woodworth, T., and Genovese, M. C. (2010) Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 69, 88-96.
15. Kishimoto, T. (2005). Interleukin-6: from basic science to medicine-40 years in immunology. Annu Rev Immunol 23, 1-21. (Pubitemid 40563163)
16. Kooloos, W. M., Huizinga, T. W., Guchelaar, H. J., and Wessels, J. A. (2010). Pharmacogenetics in treatment of rheumatoid arthritis. Curr Pharm Des 16, 164-175.
17. Looney, R. J., Anolik, J. H., Campbell, D., Felgar, R. E., Young, F., Arend, L. J., Sloand, J. A., Rosenblatt, J., and Sanz, I. (2004) B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 50, 2580-2589. (Pubitemid 39062719)
18. Magnusson, M., Brisslert, M., Zendjanchi, K., Lindh, M., and Bokarewa, M. I. (2010). Epstein-Barr virus in bone marrow of rheumatoid arthritis patients predicts response to rituximab treatment. Rheumatology (Oxford) 49, 1911-1919.
19. Mosca, M., and Bombardieri, S. (2007). Disease-specific quality indicators, guidelines, and outcome measures in systemic lupus erythematosus (SLE). Clin Exp Rheumatol 25, 107-113.
20. Oukka, M. (2008). Th17 cells in immunity and autoimmunity. Ann Rheum Dis 67 Suppl 3, iii26-9.
21. Panoulas, V. F., Stavropoulos-Kalinoglou, A., Metsios, G. S., Smith, J. P., Milionis, H. J., Douglas, K. M., Nightingale, P., and Kitas, G. D. (2009). Association of interleukin-6 (IL-6)-174G/C gene polymorphism with cardiovascular disease in patients with rheumatoid arthritis: the role of obesity and smoking. Atherosclerosis 204, 178-183.
22. Pascual, M., Nieto, A., Mataran, L., Balsa, A., Pascual-Salcedo, D., and Martin, J. (2000). IL-6 promoter polymorphisms in rheumatoid arthritis. Genes Immun 1, 338-340.
23. Pescovitz, M. D. (2006). Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action. Am J Transplant 6, 859-866. (Pubitemid 44356635)
24. Quartuccio, L., Fabris, M., Salvin, S., Atzeni, F., Saracco, M., Benucci, M., Cimmino, M., Morassi, P., Masolini, P., Pellerito, R., Cutolo, M., Puttini, P. S., and De Vita, S. (2009) Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis. Rheumatology (Oxford) 48, 1557-1559.
25. Ramos-Casals, M., Garcia-Hernandez, F. J., de Ramon, E., Callejas, J. L., Martinez-Berriotxoa, A., Pallares, L., Caminal-Montero, L., Selva-O'Callaghan, A., Oristrell, J., Hidalgo, C., Perez-Alvarez, R., Mico, M. L., Medrano, F., Gomez de la Torre, R., Diaz-Lagares, C., Camps, M., Ortego, N., and Sanchez-Roman, J. (2010) Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases. Clin Exp Rheumatol 28, 468-476.
26. Renal Disease Subcommittee of the American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria. (2006) The American College of Rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials. Arthritis Rheum 54, 421-432.
27. Rose-John, S., Scheller, J., Elson, G., and Jones, S. A. (2006). Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J Leukoc Biol 80, 227-236. (Pubitemid 44835496)
28. Santos, M. J., Fernandes, D., Capela, S., da Silva, J. C., and Fonseca, J. E. (2011). Interleukin-6 promoter polymorphism-174 G/C is associated with nephritis in Portuguese Caucasian systemic lupus erythematosus patients. Clin Rheumatol 30, 409-413.
29. Stasi, R., Pagano, A., Stipa, E., and Amadori, S. (2001). Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 98, 952-7.
30. Taylor, R. P., and Lindorfer, M. A. (2007). Drug insight: the mechanism of action of rituximab in autoimmune disease - the immune complex decoy hypothesis. Nat Clin Pract Rheumatol 3, 86-95.
31. Thurlings, R. M., Boumans, M., Tekstra, J., van Roon, J. A., Vos, K., van Westing, D. M., van Baarsen, L. G., Bos, C., Kirou, K. A., Gerlag, D. M., Crow, M. K., Bijlsma, J. W., Verweij, C. L., and Tak, P. P. (2010) Relationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patients. Arthritis Rheum 62, 3607-3614.
32. Yamamoto, M., Yoshizaki, K., Kishimoto, T., and Ito, H. (2000). IL-6 is required for the development of Th1 cell-mediated murine colitis. J Immunol 164, 4878-4882. (Pubitemid 30238092)